Project Mitigate

News Archive

Final consortium meeting in Innsbruck, AT

MITIGATE held its final consortium meeting at the Medical University in Innsbruck, Austria on September 12-13. The project will conclude at the end of September 2017.

Consortium members presented their results and achievements of the MITIGATE project over the past four years, and discussed opportunities on how to continue the fruitful collaboration after the funding period ends.

The MITIGATE clinical study shows promising results, and partners Advanced Accelerator Applications and the Medical University Innsbruck look to continue their collaboration in the development of nuclear medicine tracers for the diagnosis, and eventually treatment, of GIST.

MITIGATE has been highly successful in achieving the goals it set out at the beginning of the project and there are clear strategies for the future exploitation and marketing of MITIGATE results.

MITIGATE-5th-GA

MITIGATE newsletter – 4th edition

In its 4th newsletter, the MITIGATE consortium presents the studies conducted work packages 7 and 8: The efforts of WP7 concentrated on the development of a protocol for minimally invasive treatment and studies on robotic assistance. Within WP8, the assessment of new MR imaging methods of GIST tumour models into clinical practice has been investigated. More details on the on-going MITIGATE clinical study are also included.

You can read the newsletter here.

Final consortium meeting in Innsbruck/AT

MITIGATE partners will meet for the fifth and final general assembly on September 13th, 2017 at the Medical University of Innsbruck, Austria.

At the meeting, the final results of the project will be shared and discussed among all collaborating scientists. The consortium will focus on how these results can and will be exploited after the project concludes, in order to bring the project’s developments from the bench to the bedside and into clinical routine.

MITIGATE shares latest results at RöKo 2017

MITIGATE was recently present at the German Röntgen Congress 2017 in Leipzig, Germany. The latest results and information were shared at a dedicated project booth during the congress exhibition. Furthermore, MITIGATE organised a workshop where the project’s innovations which are ready for, or close to, the market were introduced. Project results were also introduced  and discussed by MITIGATE partners during a Highlight Session on GIST.

The German Röntgen Congress is the annual congress of the German Society of Radiology and attrachts approximately 7,000 visitors each year.

SchönbergBooth

AAA-MM-2

Innovation Workshop at German Röntgen Conress

MITIGATE will host its Innovation Workshop at the German Röntgen Congress 2017 on May 26th from 10:00-12:00. Here, the consortium will present innovations for diagnostic imaging and minimally invasive treatment which are ready for the market.

Additionally, MITIGATE will also have an exhibition booth with additional information about the project and its results and achievements.

The programme of the Innovation Workshop can be seen below:

MITIGATE Innovation Workshop Programme

 

 

Start of patient recruitment for MITIGATE clinical study

MITIGATE is recruiting patients with metastatic GIST who are experiencing tumour progression while under treatment with Imatinib (Glivec®, Gleevec™) for a diagnostic clinical study.

MITIGATE uses an innovative imaging approach focusing on progressive tumour lesions. While the approach is diagnostic rather than therapeutic, patients may derive real benefits from the new imaging procedure, such as improved tumour volume definition and better detection of disease.

European patients with metastatic GIST can fill out the enrolment questionnaire to determine whether you meet the requirements for participation in our study. You access the questionnaire by clicking here.

3rd IRDiRC Conference, February 8-9 in Paris, France

Save the date for the third International Rare Diseases Research Consortium conference in Paris, France

The third conference of the International Rare Diseases Research Consortium (IRDiRC) will take place February 8-9, 2017 in Paris, France at the conference center of Université Pierre et Marie Curie Jussieu.

Since it’s launch in 2011, IRDiRC has made considerable advances in rare diseases research. This conference presents a unique opportunity to reflect upon the progress made, confront barriers, and form new collaborations to take on challenges posed by rare diseases.

All stakeholders – active investigators, policy makers, young researchers and patient advocates alike – active in the area of rare diseases from across the globe are invited to join the IRDiRC conference to celebrate achievements in the field, identify future milestones and goals, and work toward bringing diagnoses and therapies to all rare disease patients.

More information on the IRDiRC is available on the website: www.irdirc.org

MITIGATE session at ECR 2016

The MITIGATE consortium organised a session on clinical trials in interventional radiology on the occasion of the European Congress of Radiology 2016 in Vienna. The session “MITIGATE what does it take to perform clinical trials in interventional radiology?” attracted a significant number of attendees, and discussion on setting up and running trials in interventional radiology.

mtgtecr161

Speakers and moderators, Prof. Dr. Werner Jaschke and Prof. Dr. Stefan Schönberg, were pleased to see a high interest among radiologists in the presented topics.

mtgtecr162

Click here to get more information about the session and to watch it online*

*Please note that users must register online in order to watch sessions from the ECR